Sanjiv Suri - Trinity Biotech VP America
| TRIB Stock | USD 1.13 0.09 7.38% |
Insider
Sanjiv Suri is VP America of Trinity Biotech plc
| Age | 65 |
| Address | IDA Business Park, Bray, Ireland, A98 H5C8 |
| Phone | 353 1 276 9800 |
| Web | https://www.trinitybiotech.com |
Trinity Biotech Management Efficiency
The company has return on total asset (ROA) of (0.0964) % which means that it has lost $0.0964 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.1345) %, meaning that it created substantial loss on money invested by shareholders. Trinity Biotech's management efficiency ratios could be used to measure how well Trinity Biotech manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.05, whereas Return On Tangible Assets are projected to grow to (0.53). At present, Trinity Biotech's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 69.5 M, whereas Total Assets are forecasted to decline to about 56.5 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| David King | Standard Biotools | N/A | |
| Martin Shirley | Star Equity Holdings | 61 | |
| Camilla Zuckero | Castle Biosciences | N/A | |
| MD FACR | Exagen Inc | N/A | |
| Michael Biehl | Sotera Health Co | 68 | |
| Nadia Altomare | Sera Prognostics | 53 | |
| Mark Hazeltine | Exagen Inc | 50 | |
| Jeffrey Bojar | Biodesix | N/A | |
| DVM DiplomateACVP | Inotiv Inc | 57 | |
| Michael MD | Sera Prognostics | N/A | |
| William Pitchford | Inotiv Inc | 69 | |
| Bob Halbert | Star Equity Holdings | N/A | |
| Ryan Douglas | Exagen Inc | N/A | |
| Rafael AguirreSacasa | Standard Biotools | N/A | |
| RN RN | Castle Biosciences | 56 | |
| Robert Harrison | Sera Prognostics | 58 | |
| Dr III | Biodesix | 53 | |
| Kevin Theriault | Sotera Health Co | N/A | |
| Paul Beresford | Biodesix | N/A | |
| Richard Coleman | Star Equity Holdings | 67 | |
| Matthew Molchan | Star Equity Holdings | 56 | |
Management Performance
| Return On Equity | -19.13 | ||||
| Return On Asset | -0.0964 |
Trinity Biotech plc Leadership Team
Elected by the shareholders, the Trinity Biotech's board of directors comprises two types of representatives: Trinity Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Trinity. The board's role is to monitor Trinity Biotech's management team and ensure that shareholders' interests are well served. Trinity Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Trinity Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Simon Dunne, Chief Officer | ||
| Ronan ACA, Director Founder | ||
| Fernando Devia, Ex Sales | ||
| Eibhlin Kelly, Chief Officer | ||
| Aris Kekedjian, CEO Chairman | ||
| Louise Tallon, CFO Officer | ||
| John Gillard, CEO, President | ||
| Gary Keating, Chief Officer | ||
| Adrian Donohue, Chief Officer | ||
| Ronan OCaoimh, Executive Chairman of the Board | ||
| Sanjiv Suri, VP America | ||
| Des Fitzgerald, Interim Officer | ||
| Colm Molloy, Group Culture | ||
| James Walsh, Executive Director and Member of Compensation Committee | ||
| Jacqueline ONeill, Director Operations |
Trinity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Trinity Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -19.13 | ||||
| Return On Asset | -0.0964 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 121.74 M | ||||
| Shares Outstanding | 27.32 M | ||||
| Shares Owned By Insiders | 19.68 % | ||||
| Shares Owned By Institutions | 23.90 % | ||||
| Number Of Shares Shorted | 94.13 K | ||||
| Price To Earning | 31.00 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (2.25) | Revenue Per Share 6.968 | Quarterly Revenue Growth 0.14 | Return On Assets (0.1) |
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.